Navigation Links
OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
Date:9/2/2008

BOTHELL, WA and VANCOUVER, Sept. 2 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) ("OncoGenex" or the "Company") has announced today that it has granted to Eagle Pharmaceuticals, Inc. the exclusive worldwide rights to develop and commercialize TOCOSOL(R) Paclitaxel. Under the terms of the agreement, OncoGenex is entitled to receive royalty payments from future TOCOSOL Paclitaxel sales and a percentage of sub-licensing royalty and milestone payments received by Eagle Pharmaceuticals. All development expenses are the sole responsibility of Eagle Pharmaceuticals. No upfront payments or milestone payments were included in this transaction and no further terms have been disclosed.

TOCOSOL Paclitaxel was previously developed by Sonus Pharmaceuticals prior to the combination of Sonus and OncoGenex Technologies to form the Company on August 21, 2008. In previous disclosures, the Company stated that it had terminated further development of TOCOSOL Paclitaxel and would evaluate alternative strategies for the program, including out-licensing.

"We intend to focus all of our efforts on the deep pipeline we currently have in development, including OGX-011 which is completing five Phase 2 clinical studies in prostate, breast and lung cancers," said Scott Cormack, President and CEO of OncoGenex Pharmaceuticals. "TOCOSOL Paclitaxel was not part of that strategy, and we are pleased to be able to out-license the program to an organization with interest in continuing development of this product candidate."

About OncoGenex Pharmaceuticals

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatme
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
2. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
3. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
6. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
7. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
8. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
9. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
11. Trubion Pharmaceuticals to Present at Fall 2008 Morgan Stanley Global Healthcare Unplugged Conference in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 Dr. Greg Leyer of UAS Labs ... Natural Supplements Pre-Conference seminar on probiotics in San Diego, CA. ... continuing education conference for health care professionals. This year’s pre-conference ... of probiotics in health. Dr. Leyer spoke about the emerging ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Selexis SA, ... mammalian Research Cell Banks (RCBs) used for drug discovery ... Cell Banks will include Next-Generation Sequencing (NGS) ... architecture de-risks biologic manufacturing by ensuring the integrity of ...
(Date:1/22/2015)... , Nueva Jersey , 22 de enero de ... Biomedical Research abre hoy su llamada a nominaciones para ... investigación científica ha hecho, o tiene el potencial para ... humana. Las nominaciones se aceptarán hasta el 15 de ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
Breaking Biology Technology:Selexis Generated Research Cell Banks Now Fully Sequenced Using Next-Generation Sequencing 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2
... 2011 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR ... financial results after the NASDAQ Global Market closes on ... that day at 5:00 p.m. Eastern Time (2:00 p.m. ... for the third quarter as well as provide a ...
... 2011 At the eighth annual Indiana Life Sciences ... the founder of Bloomington-based Cook Group and one of ... M. Watanabe Life Sciences Champion of the Year award.  ... a tribute to his friend and colleague. ...
... BOSTON, Oct. 26, 2011 13 leading industry speakers will ... Electronic Trial Master Files on November 14-15, 2011 in ... educational exploration of the major shift taking place in the ... Often called the heart of a clinical ...
Cached Biology Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2011 Financial Results 2BioCrossroads Awards Indiana Life Sciences Leaders 2BioCrossroads Awards Indiana Life Sciences Leaders 3BioCrossroads Awards Indiana Life Sciences Leaders 4
(Date:12/17/2014)... 15, 2014 Research and Markets ( http://www.researchandmarkets.com/research/s6qzt5/samsung_galaxy_s5 ... Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology ... http://photos.prnewswire.com/prnh/20130307/600769 Based on a ... introduces for the first time a fingerprint sensor in ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/11/2014)... and Markets , http://photos.prnewswire.com/prnh/20130307/600769 ... the addition of the "Biometrics Market in India ... One major trend emerging in this market is the ... more than one characteristic of an individual for verification ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... decrease in yield and an increase in the concentration of ... with the results of previous studies which have shown a ... seeds in high ozone, these results (to be presented at ... on 29th June 2009) could signal a significant income loss ...
... serious demands for the organism, and this is true even ... the ancestors of present marine mammals initiated their return to ... new medium. Dr. Michael Berenbrink and his colleagues at Liverpool ... delivering oxygen to the muscles during locomotion, has been modified ...
... SALT LAKE CITY, June 29, ... use computers and may let amputees control bionic limbs. But existing devices ... Utah study shows that brain signals controlling arm movements can be detected ... it. ...
Cached Biology News:Natural-born divers and the molecular traces of evolution 2Reading the brain without poking it 2Reading the brain without poking it 3Reading the brain without poking it 4Reading the brain without poking it 5
The AVR9-8 stream-select valve is a 9-port, 8-position valve for use with the BioLogic DuoFlow system. This valve is used for high-pressure stream selection....
... Versatile stain for staining RNA (bluish-purple), DNA (blue), proteins ... TLC ≥ 90 % Cation traces: Ca ≤ 10 ... Cr ≤ 5 mg/kg Cu ≤ 5 mg/kg Fe ... 5 mg/kg Mn ≤ 5 mg/kg Na ≤ 50 ...
... Biometras Tpersonal thermocycler provides maximum performance ... generation of Peltier elements, high heating and ... to short run times. With a maximum ... Tpersonal provides half the capacity of much ...
... One-Step Deparaffinization Solution is available ... is an easy-to-use reagent for dewaxing ... immunohistochemistry, in situ hybridization, or other ... paraffin removal consists of dipping the ...
Biology Products: